In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke

European Journal of Pharmacology

Volumn 474, Issue 1, 2003, Pages 53-62

  Petty, Margaret A ^a   Neumann Haefelin, Claudia ^b   Kalisch, Juergen ^b   Sarhan, Shakir ^a   Wettstein, Joseph G ^a   Juretschke, Hans Paul ^b  

^a SANOFI   (France)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Body temperature; Diffusion perfusion magnetic resonance imaging; Ischemia; Middle cerebral artery occlusion; Neurological deficit; Reperfusion

Indexed keywords

6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BRAIN PERFUSION; BRAIN PROTECTION; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG RESEARCH; HYPOTHERMIA; MALE; MEASUREMENT; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; REPERFUSION; SPECIES COMPARISON;

EID: 0142106985     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)02002-8     Document Type: Article

References (40)

1. Barone F.C., Feuerstein G.Z., Whote R.F. Brain cooling during transient focal ischemia provides complete neuroprotection. Neurosci. Biobehav. Rev. 21:1997;31-44.
2. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 17:1986;472-476.
3. Belayev L., Alonso O.F., Busto R., Zhao W., Ginsberg M.D. Middle cerebral artery occlusion in the rat by intraluminal suture: neurological and pathological evaluation of an improved model. Stroke. 27:1996;1616-1623.
4. Boast C., Gerhardt S., Pastor G., Lehmann J., Etienne P., Liebman J. The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils. Brain Res. 442:1988;345-348.
5. Bordi F., Pietra C., Ziviani L., Reggiani A. The glycine antagonist GV 150526A protects somatosensory evoked potentials and reduces the infarct area in the MCAO model of focal ischemia in the rat. Exp. Neurol. 145:1997;425-433.
6. Butcher S.P., Bullock R., Graham D.I., McCulloch J. Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke. 21:1990;1.
7. Choi D.W., Maulucci-Gedde A.R., Kriegstein A.R. Glutamate neurotoxicity in cortical cell culture. J. Neurosci. 7:1987;357-368.
8. Di X., Bullock R. Effect of the novel high-affinity glycine-site N-methyl-D-aspartate antagonist ACEA-1021 on 125I-MK-801 binding after subdural hematoma in the rat: an in vivo autoradiographic study. J. Neurosurg. 85:1996;655-661.
9. Franke C., van Dorsten F.A., Olah L., Schwindt W., Hoehn M. Arterial spin tagging perfusion imaging of rat brain: dependency on magnetic field strength. Magn. Reson. Imaging. 18:2000;1109-1113.
10. Gill R., Foster A.C., Woodruff G.N. Systemic administration of MK-801 protects against ischaemia-induced hippocampal neurodegeneration in the gerbil. J. Neurosci. 7:1987;3343-3349.
11. Gill R., Hargreaves R.J., Kemp J.A. The neuroprotective effect of the glycine site antagonist 3R-(+)-cis-4-methyl-HA966 (L-687,414) in a rat model of focal ischaemia. J. Cereb. Blood Flow Metab. 15:1995;197-204.
12. Grotta J., Picone C., Ostrow P., Strong R., Earls R., Yao L., Rhoades H., Dedman J. CGS-19755, a competitive NMDA receptor antagonist reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann. Neurol. 27:1990;612-619.
13. Hawkinson J.E., Huber K.R., Sahota P.S., Han Hsu H., Weber E., Whitehouse M. The N-methyl-D-aspartate (NMDA) receptor glycine site antagonist ACEA 1021 does not produce pathological changes in rat brain. Brain Res. 744:1977;227-234.
14. Hicks C.A., Ward M.A., Ragumoorthy N., Ambler S.J., Dell C.P., Dobson D., O'Neill M.J. Evaluation of glycine site antagonists of the NMDA receptor in global cerebral ischemia. Brain Res. 819:1999;65-74.
15. Hoehn-Berlage M., Norris D.G., Kohno K., Mies G., Leibfritz D., Hossmann K.-A. Evolution of regional changes in apparent diffusion coefficient during focal ischemia of rat brain: the relationship of quantitative diffusion NMR imaging to reduction of cerebral blood flow and metabolic disturbances. J. Cereb. Blood Flow Metab. 15:1995;1002-1011.
16. Keana J.F.W., Kher S.M., Cai S.M., Dinsmore S.X., Glenn A.G., Guastella J., Huang J.-C., Ilyin V., Lu Y., Mouser P.L., Woodward R.M., Weber E. Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: antagonism of N-methyl-D-aspartate (NMDA) receptor glycine sites and non NMDA glutamate receptors. J. Med. Chem. 38:1995;4367-4379.
17. 2*-weighted MRI. NMR Biomed. 8:1996;20-23.
18. Le Bihan D., Breton E., Lallemand D., Grenier P., Cabanis E., Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 161:1986;401-407.
19. Li F., Han S.S., Tatlisumak T., Liu K.-F., Garcia J.H., Sotak C.H., Fisher H. Reversal of acute apparent diffusion coefficient abnormalities and delayed neuronal death following transient focal cerebral ischemia. Ann. Neurol. 46:1999;333-342.
20. 2-weighted MRI. Neurology. 54:2000;689-696.
21. McCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. Br. J. Clin. Pharm. 34:1992;106-114.
22. Meldrum B., Garthwaite J. Excitatory amino acids in neurotoxicity and neurodegenerative diseases. Trends Pharmacol. Sci. 11:1990;379-386.
23. Morikawa E., Ginsberg M.D., Dietrich W.D., Duncan R.C., Kraydieh S., Globus M.Y.-T., Busto R. The significance of brain temperature in focal cerebral ischemia: histopathological consequences of middle cerebral artery occlusion in the rat. J. Cereb. Blood Flow Metab. 12:1992;380-389.
24. 2-weighted MRI and spectroscopy. Magn. Reson. Med. 14:1990;330-346.
25. Newell D.W., Barth A., Malouf A.T. Glycine site NMDA receptor antagonists provide protection against ischemia-induced neuronal damage in hippocampal slice cultures. Brain Res. 675:1995;38-44.
26. Olah L., Wecker S., Hoehn M. Secondary deterioration of apparent diffusion coefficient after 1-hour transient focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 20:2000;1474-1482.
27. Park C.K., McCulloch J., Kang J.K., Choi C.R. Efficacy of D-CP-Pene, a competitive N-methyl-D-aspartate antagonist, in focal cerebral ischemia in the rat. Neurosci. Lett. 147:1992;41-44.
28. Pelligrini-Giampietro D.E., Cozzi A., Moroni F. The glycine antagonist and free radical scavenger 7-Cl-thio-kynurate reduces CA1 ischemic damage in the gerbil. Neuroscience. 63:1994;701-709.
29. Priestley T., Horne A.L., McKernan R.M., Kemp J.A. The effect of NMDA receptor glycine site antagonist on hypoxia-induced neurodegeneration of rat cortical cell cultures. Brain Res. 53:1990;183-188.
30. Swanson R.A., Morton M.T., Tsao-Wu G., Savalos R.A., Davidson C., Sharp F.R. A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 10:1990;290-293.
31. Takaoka S., Bart R.D., Pearlstein R., Brinkhous A., Warrner D.S. Neuroprotective effect of NMDA receptor glycine recognition site antagonist persists when brain temperature is controlled. J. Cereb. Blood Flow Metab. 17:1997;161-167.
32. Tamura A., Graham D.I., McCulloch J., Teasdale G.M. Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 1:1981;53-60.
33. Tsuchida E., Bullock R. The effect of the glycine site-specific N-methyl-D-aspartate antagonist ACEA 1021 on ischemic brain damage caused by acute subdural hematoma in the rat. J. Neurotrauma. 12:1995;279-288.
34. van Lookeren Campagne M., Thomas G.R., Thibodeaux H., Palmer J.T., Williams S.P., Lowe D.G., van Bruggen N. Secondary reduction in the apparent diffusion coefficient of water, increase in cerebral blood volume, and delayed neuronal death after middle cerebral artery occlusion and early reperfusion in the rat. J. Cereb. Blood Flow Metab. 19:1999;1354-1364.
35. Warner D.S., Martin H.J., Ludwig P., McAllister A., Keana J.F.W., Weber E. In vivo models of cerebral ischemia: effects of parentally administered NMDA receptor glycine site antagonists. J. Cereb. Blood Flow Metab. 15:1995;188-196.
36. Wilding T.J., Huettner J.E. Antagonist pharmacology of kainite- and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors. Mol. Pharmacol. 49:1996;540-546.
37. Wood E.R., Bussey T.J., Phillips A.G. A glycine antagonist reduces ischemia-induced CA1 cell loss in vivo. Neurosci. Lett. 145:1992;10-14.
38. Wood E.R., Bussey T.J., Phillips A.G. A glycine antagonist 7-chlorokynurenic acid attenuates ischemia-induced learning deficits. NeuroReport. 4:1993;151-154.
39. Woodward R., Huettner J., Guastella J., Keana J., Weber E. In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol. Pharmacol. 47:1995;568-581.
40. Zea Longa E., Weinstein P.R., Carlson S., Cummins R.W. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:1989;84-91.